11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – venlafaxin

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Venlafaxin

Venlafaxin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Richardson JL, Martin F, Dunstan H, Greenall A, Stephens S, Yates LM et al. Pregnancy outcomes following maternal venlafaxine use: A prospective observational comparative cohort study. Reprod Toxicol. 2019;84(0):108-113.

  2. Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015;350:h1798.

  3. Bérard A, Zhao JP, Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open. 2017;7(1):e013372.

  4. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007;27:607-13..

  5. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001;158:1728-30.

  6. Kolding L, Ehrenstein V, Pedersen L, Sandager P, Petersen OB, Uldbjerg N,Pedersen LH. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study. BJOG. 2021 Nov;128(12):1949-1957.

  7. Forsberg L, Navér L, Gustafsson LL, Wide K. Neonatal adaptation in infants prenatally exposed to antidepressants- clinical monitoring using neonatal abstinence score. PLoS One. 2014;9:e111327.

  8. Marks C, Silvola R, Teal E, Quinney SK, Haas DM. Comparing newborn outcomes after prenatal exposure to individual antidepressants: A retrospective cohort study. Pharmacotherapy. 2021;41(11):907-914.

  9. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312-6.

  10. Nörby U, Forsberg L, Wide K, Sjörs G, Winbladh B, Källén K. Neonatal Morbidity After Maternal Use of Antidepressant Drugs During Pregnancy. Pediatrics. 2016;138:.

  11. Munk-Olsen T, Bergink V, Rommel AS, Momen N, Liu X. Association of Persistent Pulmonary Hypertension in Infants With the Timing and Type of Antidepressants In Utero. JAMA Netw Open. 2021;4(12):e2136639.

  12. Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142-51.

  13. Nakhai-Pour HR, Broy P, Bérard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ. 2010;182:1031-7.

  14. Kjaersgaard MI, Parner ET, Vestergaard M, Sørensen MJ, Olsen J, Christensen J et al. Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study. PLoS One. 2013;8(8):e72095.

  15. Ankarfeldt MZ, Petersen J, Andersen JT, Fernandes MFS, Li H, Motsko SP et al. Duloxetine Exposure During Pregnancy and the Risk of Spontaneous and Elective Abortion: A Danish Nationwide Observational Study. Drugs Real World Outcomes. 2021;8(3):289-299.

  16. Eleftheriou G, Zandonella Callegher R, Butera R, De Santis M, Cavaliere AF, Vecchio S et al. Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders. Int J Environ Res Public Health. 2023;20(16):6565.

  17. Huybrechts KF, Bateman BT, Pawar A, Bessette LG, Mogun H, Levin R et al. Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. BMJ. 2020;368(237):m237.

  18. EMA. PRAC recommendations on signals adopted at the 28 Sep-1 Oct 2020 PRAC meeting. EMA [www]. [updated 2020-10-26, cited 2024-04-10].

  19. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013;346:f2059.

  20. Rai D, Lee BK, Dalman C, Newschaffer C, Lewis G, Magnusson C. Antidepressants during pregnancy and autism in offspring: population based cohort study. BMJ. 2017;358:j2811.

  21. Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T, Vigod SN. Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children. JAMA. 2017;317(15):1544-1552.

  22. Sujan AC, Rickert ME, Öberg AS, Quinn PD, Hernández-Díaz S, Almqvist C et al. Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. JAMA. 2017;317(15):1553-1562.

  1. Richardson JL, Martin F, Dunstan H, Greenall A, Stephens S, Yates LM et al. Pregnancy outcomes following maternal venlafaxine use: A prospective observational comparative cohort study. Reprod Toxicol. 2019;84(0):108-113.
  2. Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015;350:h1798.
  3. Bérard A, Zhao JP, Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open. 2017;7(1):e013372.
  4. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007;27:607-13..
  5. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001;158:1728-30.
  6. Kolding L, Ehrenstein V, Pedersen L, Sandager P, Petersen OB, Uldbjerg N,Pedersen LH. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study. BJOG. 2021 Nov;128(12):1949-1957.
  7. Forsberg L, Navér L, Gustafsson LL, Wide K. Neonatal adaptation in infants prenatally exposed to antidepressants- clinical monitoring using neonatal abstinence score. PLoS One. 2014;9:e111327.
  8. Marks C, Silvola R, Teal E, Quinney SK, Haas DM. Comparing newborn outcomes after prenatal exposure to individual antidepressants: A retrospective cohort study. Pharmacotherapy. 2021;41(11):907-914.
  9. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312-6.
  10. Nörby U, Forsberg L, Wide K, Sjörs G, Winbladh B, Källén K. Neonatal Morbidity After Maternal Use of Antidepressant Drugs During Pregnancy. Pediatrics. 2016;138:.
  11. Munk-Olsen T, Bergink V, Rommel AS, Momen N, Liu X. Association of Persistent Pulmonary Hypertension in Infants With the Timing and Type of Antidepressants In Utero. JAMA Netw Open. 2021;4(12):e2136639.
  12. Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142-51.
  13. Nakhai-Pour HR, Broy P, Bérard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ. 2010;182:1031-7.
  14. Kjaersgaard MI, Parner ET, Vestergaard M, Sørensen MJ, Olsen J, Christensen J et al. Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study. PLoS One. 2013;8(8):e72095.
  15. Ankarfeldt MZ, Petersen J, Andersen JT, Fernandes MFS, Li H, Motsko SP et al. Duloxetine Exposure During Pregnancy and the Risk of Spontaneous and Elective Abortion: A Danish Nationwide Observational Study. Drugs Real World Outcomes. 2021;8(3):289-299.
  16. Eleftheriou G, Zandonella Callegher R, Butera R, De Santis M, Cavaliere AF, Vecchio S et al. Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders. Int J Environ Res Public Health. 2023;20(16):6565.
  17. Huybrechts KF, Bateman BT, Pawar A, Bessette LG, Mogun H, Levin R et al. Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. BMJ. 2020;368(237):m237.
  18. EMA. PRAC recommendations on signals adopted at the 28 Sep-1 Oct 2020 PRAC meeting. EMA [www]. [updated 2020-10-26, cited 2024-04-10].
  19. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013;346:f2059.
  20. Rai D, Lee BK, Dalman C, Newschaffer C, Lewis G, Magnusson C. Antidepressants during pregnancy and autism in offspring: population based cohort study. BMJ. 2017;358:j2811.
  21. Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T, Vigod SN. Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children. JAMA. 2017;317(15):1544-1552.
  22. Sujan AC, Rickert ME, Öberg AS, Quinn PD, Hernández-Díaz S, Almqvist C et al. Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. JAMA. 2017;317(15):1553-1562.